Murat Akova

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5700333/publications.pdf

Version: 2024-02-01

125 papers	14,349 citations	41344 49 h-index	20358 116 g-index
133 all docs	133 docs citations	133 times ranked	15842 citing authors

#	Article	IF	Citations
1	Do antimicrobial stewardship programs improve the quality of care in ICU patients diagnosed with infectious diseases following consultation? Experience in a tertiary care hospital. International Journal of Infectious Diseases, 2022, 115, 201-207.	3.3	4
2	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	32.4	
3	A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting. International Journal of Antimicrobial Agents, 2022, 59, 106554.	2.5	13
4	The Role of Colistin in the Era of New Î²-Lactam/Î²-Lactamase Inhibitor Combinations. Antibiotics, 2022, 11, 277.	3.7	18
5	Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia. Microorganisms, 2022, 10, 733.	3.6	6
6	Vorikonazol TerapÃ¶tik Ä°laÃ§ DÃ¼zeyi Ä°zlemi: Bir Ãœniversite Hastanesi Deneyimi. Flora: the Journal of Infectious Diseses and Clinical Microbiology = Infeksiyon HastalÄ±klarÄ± Ve Klinik Mikrobiyoloji Dergisi, 2022, 27, 183-188.	0.1	1
7	Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 841-847.	2.9	17
8	Is there still a room for improvement in antimicrobial use in a setting where use of broad-spectrum antibiotics require approval of an infectious diseases physician?. Infection Control and Hospital Epidemiology, 2022, , 1-3.	1.8	0
9	COVID-19 vaccine booster strategy: striving for best practice. The Lancet Global Health, 2022, 10, e774-e775.	6.3	3
10	Factors Associated with Gram-Negative Bacteremia and Mortality in Neutropenic Patients with Hematologic Malignancies in a High-Resistance Setting. Infectious Diseases and Clinical Microbiology, 2022, 4, 87-98.	0.3	0
11	Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey. Vaccines, 2022, 10, 1140.	4.4	6
12	Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. European Radiology, 2021, 31, 1090-1099.	4.5	48
13	Expect the unexpected: fungemia caused by uncommon Candida species in a Turkish University Hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1539-1545.	2.9	3
14	Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. Turkish Journal of Medical Sciences, 2021, 51, 411-420.	0.9	14
15	A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 276.	1.6	24
16	Pulmonary nocardiosis caused by Nocardia abscessus mimicking pulmonary thromboembolism in a patient with atypical anti-glomerular basement membrane glomerulonephritis. Tuberkuloz Ve Toraks, 2021, 69, 237-241.	0.4	1
17	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, The, 2021, 398, 213-222.	13.7	683
18	Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study. Journal of Infection, 2021, 83, 175-181.	3.3	17

#	Article	IF	Citations
19	COVID-19 Vaccination in The Wake of a Fourth Wave of the Pandemic: An Evidence-Based Strategy is Desperately Needed. Infectious Diseases and Clinical Microbiology, 2021, 3, 52-54.	0.3	3
20	Gram-Negative Infections. Hematologic Malignancies, 2021, , 161-179.	0.2	2
21	CoronaVac efficacy data from Turkey â€“ Authors' reply. Lancet, The, 2021, 398, 1874.	13.7	3
22	End of Year, Editorial 2021. Infectious Diseases and Clinical Microbiology, 2021, 3, 109-109.	0.3	0
23	Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 385-392.	2.9	9
24	Factors associated with severe lung disease in an adult population with cystic fibrosis: a single-center experience. Turkish Journal of Medical Sciences, 2020, 50, 945-952.	0.9	0
25	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, 46, 1404-1417.	8.2	54
26	Fungaemia due to rare yeasts in a tertiary care university centre within 18 years. Mycoses, 2020, 63, 488-493.	4.0	10
27	The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turkish Journal of Medical Sciences, 2020, 50, 679-683.	0.9	139
28	Understanding resistance in Pseudomonas. Intensive Care Medicine, 2020, 46, 350-352.	8.2	5
29	Dual Role of gnaA in Antibiotic Resistance and Virulence in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	23
30	Infections in the Elderly Critically-Ill Patients. Frontiers in Medicine, 2019, 6, 118.	2.6	75
31	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infectious Diseases, The, 2019, 19, e405-e421.	9.1	970
32	Extended spectrum Î²-lactamase producing enterobacteriaceae: carbapenem sparing options. Expert Review of Anti-Infective Therapy, 2019, 17, 969-981.	4.4	17
33	Immigrants as donors and transplant recipients: specific considerations. Intensive Care Medicine, 2019, 45, 401-403.	8.2	9
34	Impact of antibiotic resistance on outcomes of neutropenic cancer patients withPseudomonas aeruginosabacteraemia (IRONIC study): study protocol of a retrospective multicentre international study. BMJ Open, 2019, 9, e025744.	1.9	4
35	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp>gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
36	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.8	49

#	Article	IF	Citations
37	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Medicine, 2018, 44, 189-196.	8.2	101
38	Neuroinvasive Listeriosis. Neurologist, 2018, 23, 86-91.	0.7	2
39	Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection, 2018, 76, 20-37.	3.3	125
40	1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI). Open Forum Infectious Diseases, 2018, 5, S434-S435.	0.9	0
41	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-Î²-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
42	Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. Lancet Infectious Diseases, The, 2017, 17, 400-410.	9.1	177
43	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
44	Clinical efficacy of Î²-lactam/Î²-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). BMJ Open, 2017, 7, e013268.	1.9	8
45	An overview on severe infections in Europe. Intensive Care Medicine, 2017, 43, 686-689.	8.2	6
46	Efficacy of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	41
47	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
48	Bacteremic and non-bacteremic pneumonia caused by Acinetobacter baumannii in ICUs of South China: A Clinical and Microbiological Study. Scientific Reports, 2017, 7, 15279.	3.3	9
49	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. European Journal of Internal Medicine, 2017, 37, 13-18.	2.2	21
50	High prevalence of ESBL-producingEscherichia coliandKlebsiella pneumoniaein community-onset bloodstream infections in China. Journal of Antimicrobial Chemotherapy, 2017, 72, 273-280.	3.0	93
51	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
52	Antimicrobial Stewardship in Hematology Patients. , 2017, , 205-217.		0
53	ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017002.	1.3	8
54	Reducing the impact of carbapenem-resistant Enterobacteriaceae on vulnerable patient groups. Current Opinion in Infectious Diseases, 2016, 29, 555-560.	3.1	9

#	Article	IF	Citations
55	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
56	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
57	Epidemiology of carbapenem-resistant Klebsiella pneumoniae colonization: a surveillance study at a Turkish university hospital from 2009 to 2013. Diagnostic Microbiology and Infectious Disease, 2016, 85, 466-470.	1.8	22
58	Epidemiology of antimicrobial resistance in bloodstream infections. Virulence, 2016, 7, 252-266.	4.4	153
59	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
60	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	3.0	129
61	Prospective Evaluation of Infection Episodes in Cancer Patients in a Tertiary Care Academic Center: Microbiological Features and Risk Factors for Mortality. Turkish Journal of Haematology, 2016, 33, 311-319.	0.5	11
62	Epidemiology of candidaemia in a tertiary care university hospital: 10â€year experience with 381 candidaemia episodes between 2001 and 2010. Mycoses, 2015, 58, 498-505.	4.0	24
63	Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infectious Diseases, 2015, 47, 686-693.	2.8	45
64	The global threat of antimicrobial resistance: science for intervention. New Microbes and New Infections, 2015, 6, 22-29.	1.6	811
65	Discontinuation of empirical antibiotic therapy in neutropenic leukaemia patients with fever of unknown origin is ethical. Clinical Microbiology and Infection, 2015, 21, e25-e27.	6.0	23
66	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	5.8	108
67	Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Medicine, 2015, 41, 2057-2075.	8.2	133
68	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: TableÂ1. Thorax, 2015, 70, 984-989.	5.6	224
69	Evaluation of a new chromogenic medium, chromID OXA-48, for recovery of carbapenemase-producing Enterobacteriaceae from patients at a university hospital in Turkey. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 519-525.	2.9	22
70	Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4). Turkish Journal of Haematology, 2015, 32, 100-117.	0.5	6
71	Microbiological Background. , 2015, , 63-87.		0
72	Molecular characterization of NDM-1-producing Acinetobacter pittii isolated from Turkey in 2006. Journal of Antimicrobial Chemotherapy, 2014, 69, 3437-3438.	3.0	21

#	Article	IF	Citations
73	Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. Journal of Infection, 2014, 68, 321-331.	3.3	223
74	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clinical Microbiology and Infection, 2014, 20, 27-46.	6.0	383
75	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clinical Microbiology and Infection, 2014, 20, 47-75.	6.0	262
76	ESCMIDâ€ and ECMMâ€¡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection, 2014, 20, 5-26.	6.0	547
77	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	2.5	48
78	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clinical Microbiology and Infection, 2014, 20, 76-98.	6.0	400
79	Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2014, 58, 851-858.	3.2	91
80	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843
81	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	5.8	2
82	Risk factors for target non-attainment during empirical treatment with Î²-lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	8.2	147
83	The features of infectious diseases departments and anti-infective practices in France and Turkey: a cross-sectional study. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1591-1599.	2.9	2
84	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	5.8	87
85	Multidrug-resistant bacteria in solid organ transplant recipients. Clinical Microbiology and Infection, 2014, 20, 49-73.	6.0	136
86	The risk of pneumococcal diseases in lung diseases and the importance of adult vaccination. Tuberkuloz Ve Toraks, 2014, 62, 154-159.	0.4	1
87	A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. Journal of Antimicrobial Chemotherapy, 2013, 68, iii25-iii33.	3.0	12
88	Oral Antibiotics for Fever in Low-Risk Neutropenic Patients With Cancer: A Double-Blind, Randomized, Multicenter Trial Comparing Single Daily Moxifloxacin With Twice Daily Ciprofloxacin Plus Amoxicillin/Clavulanic Acid Combination Therapyâ€"EORTC Infectious Diseases Group Trial XV. Journal of Clinical Oncology, 2013, 31, 1149-1156.	1.6	72
89	Management of febrile neutropenia in the era of bacterial resistance. Therapeutic Advances in Infectious Disease, 2013, 1, 37-43.	1.8	30
90	The Place and the Efficacy of Infectious Disease Consultations in the Hospitals. Infectious Diseases in Clinical Practice, 2012, 20, 131-136.	0.3	7

#	Article	IF	Citations
91	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection, 2012, 18, 53-67.	6.0	280
92	Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clinical Microbiology and Infection, 2012, 18, 413-431.	6.0	727
93	Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clinical Microbiology and Infection, 2012, 18, 439-448.	6.0	170
94	GRACE and the development of an education and training curriculum. Clinical Microbiology and Infection, 2012, 18, E308-E313.	6.0	4
95	Leading infectious diseases problems in Turkey. Clinical Microbiology and Infection, 2012, 18, 1056-1067.	6.0	25
96	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clinical Microbiology and Infection, 2012, 18, 1-8.	6.0	91
97	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection, 2012, 18, 9-18.	6.0	310
98	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clinical Microbiology and Infection, 2012, 18, 19-37.	6.0	977
99	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. Clinical Microbiology and Infection, 2012, 18, 38-52.	6.0	264
100	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clinical Microbiology and Infection, 2012, 18, 68-77.	6.0	81
101	Laboratory-acquired brucellosis in Turkey. Journal of Hospital Infection, 2012, 80, 326-330.	2.9	24
102	A novel fungal pathogen under the spotlight -Acremonium spp. associated fungaemia in an immunocompetent host. Mycoses, 2011, 54, 78-80.	4.0	17
103	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clinical Microbiology and Infection, 2011, 17, 1859-1867.	6.0	566
104	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, 2011, 17, 1-12.	6.0	113
105	Low-level laser therapy supported teeth extractions of two patients receiving IV zolendronate. Lasers in Medical Science, 2011, 26, 569-575.	2.1	18
106	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 2011, 66, i5-i14.	3.0	178
107	Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clinical Microbiology and Infection, 2010, 16, 102-111.	6.0	216
108	Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplantation, 2009, 44, 467-470.	2.4	51

#	Article	IF	Citations
109	Sulbactam-containing Î²-lactamase inhibitor combinations. Clinical Microbiology and Infection, 2008, 14, 185-188.	6.0	55
110	The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. International Journal of Infectious Diseases, 2008, 12, 71-79.	3.3	71
111	Metallo-Î²-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	2.5	134
112	Emerging problem pathogens: A review of resistance patterns over time. International Journal of Infectious Diseases, 2006, 10, S3-S8.	3.3	15
113	Treatment of invasive infections due to rare or emerging yeasts and moulds. Expert Opinion on Pharmacotherapy, 2006, 7, 1181-1190.	1.8	6
114	Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-Î²-naphthylamide. Journal of Antimicrobial Chemotherapy, 2006, 57, 970-974.	3.0	148
115	Infectious complications in patients with hematological malignancies consulted by the Infectious Diseases team: a retrospective cohort study (1997â€“2001). Supportive Care in Cancer, 2006, 14, 52-55.	2.2	24
116	Developing and evaluating professionalism. Medical Teacher, 2006, 28, 36-39.	1.8	27
117	Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases, 2006, 43, 1031-1039.	5.8	3
118	Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. Journal of Antimicrobial Chemotherapy, 2006, 57, 344-348.	3.0	103
119	PREDICTORS OF SHORT-TERM OUTCOME OF SPONTANEOUS BACTERIAL PERITONITIS IN TURKISH CIRRHOTIC PATIENTS. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 657-660.	2.8	8
120	A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of Secondary Infections in Febrile, Neutropenic Patients with Cancer. Clinical Infectious Diseases, 2005, 40, 239-245.	5.8	56
121	Nosocomial bloodstream infections in a Turkish university hospital: study of Gram-negative bacilli and their sensitivity patterns. International Journal of Antimicrobial Agents, 2001, 17, 477-481.	2.5	10
122	Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. International Journal of Pharmaceutics, 2001, 213, 153-161.	5.2	11
123	Occupational Risk of Hepatitis B and C Infections in Urologists. Urologia Internationalis, 1998, 61, 206-209.	1.3	3
124	Comparative In Vitro Activity of Sparfloxacin against Gram-Positive Cocci. Drugs, 1993, 45, 199-200.	10.9	0
125	A Case of Crimean-Congo Haemorrhagic Fever (CCHF) Mimicking the COVID-19 Disease. Acta Medica, 0, , .	0.2	0